市場調查報告書
商品編碼
1383404
到 2030 年臨床試驗患者招募服務的市場預測:按治療領域、階段、年齡層和地區進行的全球分析Clinical Trial Patient Recruitment Services Market Forecasts to 2030 - Global Analysis By Therapeutic Areas, Phase, Age Group and By Geography |
根據 Stratistics MRC 的數據,2023 年全球臨床試驗患者招募服務市場規模為 11.9 億美元,預計在預測期內年複合成長率為 11.5%,到 2030 年將達到 25.5 億美元。
專門幫助研究人員和製藥公司尋找和招募合格的臨床試驗患者進行臨床試驗的服務稱為臨床試驗患者招募服務。為了更快開始臨床試驗,病患招募服務可以加快識別和招募合格參與者的過程。為了讓研究人員更了解治療方法在不同人群中的有效性和安全性,擁有更多樣化和代表性的患者群體至關重要,而這可以透過患者招募服務來保證,這是一個要素。
根據 ClinicalTrial.gov 統計,過去年度臨床試驗增加了 49.2%。
推動臨床試驗患者招募服務市場的主要因素之一是臨床試驗數量的增加。藥物研究、醫學研究以及對新療法和治療方法的探索的持續發展是臨床試驗活動增加的主要驅動力。隨著製藥和生物技術公司、學術機構和研究機構配合措施將新藥、醫療設備和治療方法推向市場,對專業患者招募服務的需求不斷增加。
預算限制是研究機構和製藥公司的典型問題。病患招募服務對於臨床實驗的順利進行至關重要,但其成本是一個主要因素。這些服務通常涉及大量成本,包括僱用員工、使用最尖端科技、廣告和推廣計劃來尋找和聯繫潛在的臨床試驗參與者。此外,患者招募服務提供者可能會感到在競爭激烈的市場中提供競爭的價格的壓力,這可能會影響報酬率以及投資尖端策略和技術的能力。因此,這是市場成長的主要障礙。
許多招聘機構正在利用人工智慧和資料分析等先進技術來提高參與者識別的準確性和效率。患者招募服務擴大使用資料分析,透過篩選大型資料來快速且準確地識別潛在的臨床試驗參與者。這種分析方法可以透過系統地評估各種患者特徵和病歷來確定符合每個臨床試驗確切要求的人。這些因素正在推動市場需求。
臨床試驗的法規環境複雜且不斷變化。招聘機構可能會發現很難遵守不斷變化的法規,例如資料保護和知情同意法規。此外,對於適用於臨床試驗的病患隱私、資料保護和知情同意也有嚴格的法規。患者招募服務可能難以遵守法規機構關於患者資料收集、儲存和共用的嚴格準則。這些因素都阻礙了市場的擴張。
COVID-19 大流行對臨床試驗患者招募服務市場產生了重大影響。許多正在進行的臨床試驗因疫情而中斷,這對臨床試驗入組和患者招募產生了重大負面影響。逐步淘汰、旅行禁令和使用醫療設施的限制使得臨床實驗難以按計劃進行。患者招募服務與高科技公司合作,提高遠端監控能力並收集即時患者資料,同時最大限度地減少親自就診的需要。
預計呼吸系統疾病領域將佔最大佔有率。臨床試驗招募服務呼吸疾病部門專注於臨床研究的特定領域,致力於開發各種呼吸系統疾病的治療方法。臨床試驗對於評估新藥、吸入器、生物製藥和醫療設備增強肺功能、減輕症狀和預防病情惡化的安全性和有效性至關重要。
預計二期業務在預測期內將出現良好成長。在臨床研究中,II期臨床試驗是I期試驗之後、III期試驗前發生的重要階段。 II 期臨床試驗的主要目的是評估新治療方法和藥物在較大患者群體中的安全性和有效性。 II 期臨床試驗病患招募服務負責識別和招募符合臨床實驗試驗方案中具體要求的合格參與者。
由於北美正在進行大量活躍的臨床試驗,因此在估計期間佔據最大的市場佔有率,預計市場將快速擴張。該產業也受到大量研發支出和政府對臨床試驗的資助的推動。北美的行業成長是由頂級委外研發機構(CRO) 的存在推動的,這些組織提供患者招募等廣泛的支援服務,以及全球製藥和生物製藥公司的積極參與。
預計亞太地區在預測期內將實現盈利成長。臨床試驗向印度、日本和韓國等新興國家的離岸外包正在增加。這是因為患者群龐大且臨床試驗成本低廉,進一步促進了區域擴張。合格的醫療人員、強大的醫院網路以及研發基礎設施的發展都有助於亞太市場的擴張。
According to Stratistics MRC, the Global Clinical Trial Patient Recruitment Services Market is accounted for $1.19 billion in 2023 and is expected to reach $2.55 billion by 2030 growing at a CAGR of 11.5% during the forecast period. Services specifically designed to assist researchers and pharmaceutical companies in finding and recruiting qualified subjects for their clinical trials are known as clinical trial patient recruitment services. In order to help clinical trials get underway more quickly, patient recruitment services can speed up the process of identifying and enrolling eligible participants. For researchers to better understand a treatment's efficacy and safety across a range of demographic groups it is imperative to have a more diverse and representative patient population, which is a factor that patient recruitment services can help ensure.
According to ClinicalTrial.gov, there has been a 49.2% rise in clinical trials over the past 5 years.
One major factor propelling the market for clinical trial patient recruitment services is the rise in the number of clinical trials. The ongoing developments in pharmaceutical research, medical research, and the search for novel therapies and treatments are the main drivers of this rise in clinical trial activity. Specialized patient recruitment services are in increasing demand as pharmaceutical and biotechnology companies, academic institutions, and research organizations step up their efforts to introduce novel drugs, medical devices, and therapies to the market.
Budgetary restrictions are a typical problem for research institutions and pharmaceutical companies. Although patient recruitment services are essential to the smooth running of trials, their costs can be a significant factor. These services usually come with a number of costs, such as hiring staff, using cutting-edge technologies, advertising, and outreach programs to find and connect possible trial participants. Furthermore, providers of patient recruitment services may feel pressured to offer competitive pricing in a market that is fiercely competitive, which could affect their profit margins and capacity to make investments in cutting-edge tactics and technologies. Therefore, it is a significant barrier to market growth.
Numerous recruitment agencies use advanced technologies, like artificial intelligence and data analytics, to improve participant identification accuracy and efficiency. Data analytics is being used by patient recruitment services in increasing numbers to quickly and accurately identify possible trial participants by sorting through large datasets. This analytical method makes it possible to identify people who fit the precise requirements of each clinical trial by methodically evaluating a variety of patient characteristics and medical histories. These factors propel market demand.
The regulatory landscape for clinical trials is complex and subject to constant change. Recruitment agencies may find it difficult to remain compliant with changing regulations, such as those pertaining to data protection and informed consent. Additionally, there are stringent regulations pertaining to patient privacy, data protection, and informed consent that apply to clinical trials. Patient recruitment services may find it difficult to comply with regulatory bodies' strict guidelines when it comes to gathering, storing, and sharing patient data. These factors hamper market expansion.
The COVID-19 pandemic has had a significant impact on the clinical trial patient recruitment services market. Numerous ongoing clinical trials were disrupted by the pandemic, which had a significant negative impact on trial enrolment and patient recruitment. Phase-outs, travel bans, and restricted access to medical facilities made it difficult to carry out trials as scheduled. In order to improve remote monitoring capabilities and collect real-time patient data while minimizing the need for in-person visits, patient recruitment services worked with tech companies.
The respiratory diseases segment is estimated to hold the largest share. The Clinical Trial Patient Recruitment Services' respiratory diseases section focuses on a particular field of clinical research that is committed to the creation of cures and treatments for a range of respiratory ailments. For the purpose of assessing the safety and effectiveness of novel medications, inhalers, biologics, and medical devices intended to enhance lung function, reduce symptoms, or stop exacerbations, clinical trials are crucial.
The phase II segment is anticipated to have lucrative growth during the forecast period. In the clinical research spectrum, Phase II clinical trials are a crucial stage that comes after Phase I trials and before Phase III trials. The main goals of Phase II trials are to evaluate a new treatment or medication's safety and effectiveness in a larger patient population. The Phase II segment recruitment services are responsible for identifying and enrolling eligible participants who meet the precise requirements specified in the trial protocol.
North America commanded the largest market share during the extrapolated period due to the large number of active clinical trials in the region, the market is anticipated to increase rapidly. Significant R&D expenditures and government funding for clinical studies also drive the industry. The industry's growth in North America has been facilitated by the existence of top contract research organizations (CROs) that provide extensive support services, such as patient recruiting, and by the active involvement of global pharmaceutical and biopharmaceutical corporations.
Asia Pacific is expected to witness profitable growth over the projection period. There is an increase in off shoring clinical trials to emerging economies like India, Japan, South Korea, and others. This is because there is a large patient pool and trials are inexpensive, which further promotes regional expansion. The availability of qualified medical professionals, a robust hospital network, and developed clinical research infrastructure are all contributing to the Asia-Pacific market's expansion.
Some of the key players in the Clinical Trial Patient Recruitment Services Market include: Clinical Site Services, Clara Health, Worldwide Clinical Trials, Clariness, Veristat, PPD Inc, BBK Worldwide, Elligo Health Research, Antidote Technologies, Inc., IQVIA, Matthews Media Group Inc., Conduent, Inc., Biorasi, LLC, Trialfacts and Syneos Health.
In August 2023, Worldwide Clinical partners with Cybin for psychedelic-based treatments. Cybin, a biopharma developing psychedelic-based treatment options for mental health issues.
In December 2021, worldwide clinical Trials and WCG partner to accelerate and streamline global safety event distribution. Worldwide offers a comprehensive suite of pharmacovigilance capabilities, including a regulatory intelligence database that is unique to the company and enhanced by WCG's proprietary Safety Vigilance portal.